A 58-year-old man from rural Maharashtra presents with a 6-month history of altered bowel habits and weight loss. Colonoscopy reveals a stenosing lesion in the sigmoid colon with biopsy-confirmed adenocarcinoma. Which of the following molecular/genetic alterations is NOT typically associated with the development of colorectal adenocarcinoma via the adenoma-carcinoma sequence?

Explanation

## Molecular Pathogenesis of Colorectal Adenocarcinoma ### The Adenoma-Carcinoma Sequence (Fearon-Vogelstein Model) **Key Point:** Colorectal cancer develops through a stepwise accumulation of genetic alterations in the adenoma-carcinoma sequence: ```mermaid flowchart LR A[Normal epithelium]:::outcome --> B[APC loss]:::action B --> C[Early adenoma]:::outcome C --> D[KRAS activation]:::action D --> E[Intermediate adenoma]:::outcome E --> F[TP53 loss]:::action F --> G[Late adenoma/Carcinoma]:::outcome ``` ### Key Genetic Alterations in CRC **High-Yield:** The classic sequence involves: | Gene | Type | Frequency | Role in Pathogenesis | |------|------|-----------|----------------------| | APC | Tumor suppressor | 80% of sporadic CRC | Initiating event; loss of Wnt pathway regulation | | KRAS | Oncogene | 40–50% of CRC | Promotes proliferation; occurs in adenoma stage | | TP53 | Tumor suppressor | 50–70% of CRC | Loss drives adenoma-to-carcinoma transition | | SMAD2/SMAD4 | Tumor suppressor | 30% of CRC | TGF-β pathway inactivation | | HER2 | Oncogene | <5% of CRC | NOT a typical driver in CRC | **Clinical Pearl:** HER2 amplification is a hallmark of gastric and breast cancers, not colorectal cancer. While rare HER2-positive CRCs exist (<5%), HER2 is NOT a typical molecular driver of the adenoma-carcinoma sequence. ### APC Loss — The Initiating Event **Key Point:** Loss of APC is the earliest and most frequent alteration: - Occurs in ~80% of sporadic colorectal cancers - Leads to dysregulation of the Wnt/β-catenin pathway - Causes adenoma initiation - Found in adenomas as small as 1 mm ### KRAS Activation **High-Yield:** KRAS mutations occur in 40–50% of colorectal adenocarcinomas: - Typically arise in intermediate-sized adenomas - Promote cellular proliferation and survival - Associated with worse prognosis in some studies - Predict resistance to EGFR inhibitors (anti-EGFR therapy not effective in KRAS-mutant tumors) ### TP53 Inactivation **Key Point:** TP53 loss is a late event: - Occurs in 50–70% of colorectal cancers - Marks the transition from adenoma to carcinoma - Loss of p53 function removes apoptotic checkpoints - Associated with progression to invasive disease ### HER2 in Colorectal Cancer **Warning:** Do NOT confuse HER2 status between cancer types: - **Gastric cancer:** HER2 amplification in 15–20%; trastuzumab approved - **Breast cancer:** HER2 amplification in 15–20%; trastuzumab standard - **Colorectal cancer:** HER2 amplification in <5%; NOT a typical driver; HER2-targeted therapy not standard **Clinical Pearl:** The primary targetable pathways in CRC are EGFR (in KRAS wild-type tumors) and BRAF (in BRAF-mutant tumors), not HER2.